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Pediatric Bloodstream Infections by
Results. We identified 34 children with C. auris BSI. Cases appeared to cluster in time within each hospital (Figure 1 ). Twenty-two (65%) patients were male, 21% were <28 days old, 47% were 29-365 days old, and 32% were >1 year. Underlying conditions included preterm birth (26%), altered nutritional status (59%), cancer (12%), solid-organ transplant (3%), and renal disease (3%). Eighty-two percent had a central venous catheter (CVC), 82% on respiratory support, 56% received total parenteral nutrition (TPN), 15% had a surgical procedure, and 9% received hemodialysis. All patient received antibiotics in the 14 days before C. auris BSI, and 97% received antifungal treatment for BSI. Median inpatient stay before onset of C. auris BSI was 22 days (interquartile range: 17-30 days), and in-hospital mortality was 41%.
Conclusion. Similar to other Candida BSI, C. auris affects children with a variety of medical conditions including prematurity, malignancy, and those with CVCs, and receiving TPN. Mortality was high, with nearly half of patients dying before discharge. However, unlike most other Candida species, C. auris can be transmitted in healthcare settings, as suggested by the close clustering of cases in time at each of the hospitals. Pediatric wards should be vigilant for C. auris outbreaks and take necessary infection control measures to stop the spread of the organism. Background. Candida auris is an emerging multi-drug-resistant human pathogen. Experimental data on the pathogenicity of C. auris is scarce, especially regarding its virulence compared with C. albicans. Additionally, studies of drug efficacy against C. auris rely on conventional animal models that are laborious and low throughput; alternative, less cumbersome models are desirable. To that end, we developed a C. auris fly infection model.
Methods. We injected 2-week-old Toll
I-RXA /Toll r632 female flies with a needle dipped in Candida solutions (10 8 yeast cells/mL) in the dorsal side of the thorax. Flies were infected with 10 different C. auris strains (source: CDC/FDA) and a C. albicansclinical strain. For drug protection studies, C. auris isolate AR-BANK#0386 [MICs: fluconazole (FLC) > 64, posaconazole (POSA) 0.125-0.25, isavuconazole (ISA) 0.25-1, voriconazole (VRC) 0.5-2 µg/mL)] was used. We assessed survival differences associated with different inocula (10 7 to 10 10 yeast cells/mL) and yeast strains. Moreover, protection conferred by addition of FLC, VRC, ISA, POSA, or FLC combined with 5-FC (flucytosine) and/or nikkomycin Z (NikZ) to fly food was studied. Three independent runs were performed for each experiment.
Results. A) All C. auris strains and C. albicans exhibited comparable in vitro growth rates. B) All strains of C. auris were similarly more virulent than C. albicans (P < 0.0001), with all flies dying by day 7 post-infection. C) FLC, VRC, ISA, FLC+5-FC, FLC+NikZ, or FLC+NikZ+5-FC-fed flies infected with C. auris #0386 had comparably poor survival outcomes compared with untreated C. auris #0386-infected flies. Interestingly, survival rates were improved in POSA-fed infected flies compared with Background. Activation of the cell wall integrity pathway and enhanced cell wall chitin synthesis are compensatory mechanisms associated with the incomplete killing of Candida glabrata by echinocandins. Echinocandin-induced morphologic changes in C. glabrata have also been described, yet their correlation with cell wall composition and macrophage responses to echinocandin treated C. glabrata are not well characterized. Elucidating these relationships is needed to understand how C. glabrata is capable of resisting both echinocandin killing and host immune responses.
Methods. Three echinocandin-susceptible bloodstream isolates of C. glabrata were grown in liquid RPMI with or without inhibitory concentrations of micafungin (MFG; 0.004 µg/mL) or caspofungin (CAS; 0.008 µg/mL). Cells were stained with fluorescent markers specific for cell wall chitin, mannan, and viability, then imaged utilizing high-content single-cell techniques. Phenotypic characteristics of C. glabrata cells that survive echinocandin exposure were determined by comparing the morphology and abundance cell wall components among the viable and nonviable cell subpopulations. To identify cellular characteristics associated with reduced macrophage phagocytosis, CAS or MFG treated cells were co-incubated RAW 264.7 macrophage and imaged as above. Phenotypic characteristics of the nonphagocytized yeast cells before and after co-incubation with macrophage was compared.
Results. Compared with untreated controls, growth in MFG and CAS significantly increased the proportion of cells with multiple-buds (50% ± 10% and 40% ± 18% vs. 12% ± 6%; P < 0.001) and induced cellular enlargement (biovolume; 35 ± 9 µm 3 and 80 ± 58 µm 3 vs. 26 ± 5 µm 3 ; P < 0.001). Cell enlargement, reduced cell wall mannan, and increased chitin were highly correlated with survival to MFG and CAS exposure (P < 0.001). Comparison of the drug-exposed yeast cell population before and after co-incubation with macrophage found an increased proportion of viable cells and cells with a large diameter (≥7 µM) remained un-phagocytized, indicating strong phagocytic preference for small, nonviable yeast cells.
Conclusion. C. glabrata cells that survive echinocandins have distinct cell wall changes and are large in size. These cells tend to evade phagocytosis by macrophages, suggesting a potential mechanism by which C. glabrata may persist despite echinocandin treatment.
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